Wegovy And Pediatric Obesity: A New Treatment Approach!

Obesity is a growing health concern for children and adolescents worldwide. In the United States, approximately 14.4 million children aged 2-19 years have obesity. Left untreated, pediatric obesity can lead to serious health complications including type 2 diabetes, high blood pressure, high cholesterol, asthma, sleep apnea, joint problems, fatty liver disease, gallstones, and gastro-esophageal reflux disease.

Obese children are also more likely to become obese adults, putting them at risk for heart disease, stroke, and some types of cancer. Finding safe and effective treatments for pediatric obesity is crucial.

Wegovy (semaglutide) is a new drug recently approved by the FDA for chronic weight management in adults. Research is now looking at the potential of using Wegovy off-label to treat obesity in adolescents.

This article will explore the current research on Wegovy and its possible benefits and risks when used for pediatric obesity.

Overview Of Wegovy

Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist administered as a weekly injection. It mimics the effects of GLP-1, a hormone released from the gut after eating that promotes feelings of fullness and satiety. Wegovy works by slowing digestion and reducing appetite.


In clinical trials with adults, Wegovy has been shown to lead to significant weight loss, with an average loss of 15% of body weight over 68 weeks.

Common side effects include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, and hypoglycemia in patients with type 2 diabetes.

Wegovy carries a boxed warning for thyroid C-cell tumor risk due to its mechanism of action. No cases have been reported in clinical trials, but it remains an important potential risk. Healthcare providers are advised to monitor thyroid function before and during treatment.

Research On Wegovy For Pediatric Obesity

While Wegovy is only FDA-approved for patients 18 years and older, emerging research is examining its effects on adolescents with obesity.

In one major placebo-controlled trial published in 2022 in the New England Journal of Medicine, 201 adolescents aged 12-17 years with obesity were randomly assigned to receive Wegovy or placebo for 56 weeks. Those who received Wegovy had significantly greater reductions in BMI compared to the placebo group.

Additionally, youth treated with Wegovy had improvements in cardiometabolic risk factors. The most common side effects were gastrointestinal in nature. This study provides evidence that Wegovy may be effective for weight loss in adolescents, but longer-term safety needs to be assessed.

Some experts have proposed using Wegovy off-label in children under 12 years old as well. A 2022 viewpoint paper in JAMA Pediatrics noted that lifestyle interventions are insufficient for many children with severe obesity.

The authors argue that Wegovy is a promising option given the efficacy and safety demonstrated in the adolescent trial. However, clinical trials specifically testing Wegovy in younger pediatric populations are still needed.

Potential Benefits Of Wegovy For Pediatric Obesity

Using Wegovy for pediatric obesity treatment offers several potential benefits:

  • Greater weight loss compared to lifestyle changes alone
  • Improvement in weight-related comorbidities like high blood pressure and cholesterol
  • Delay or prevention of serious adult health complications
  • Increased self-esteem and reduced bullying/stigma
  • Easier weight loss early in life before obesity is entrenched
  • Potential to help families improve diet and exercise habits together

Achieving healthy weight earlier in childhood could significantly impact long-term health outcomes. Even modest weight loss can have benefits.

Potential Risks And Precautions

While Wegovy shows promise for treating pediatric obesity, there are several risks and concerns to consider:

  • Limited long-term safety data in youth
  • Potential for slowed growth and bone density loss
  • Unknown effects on brain development and maturation
  • Psychological side effects like anxiety, depression, disordered eating
  • Need for careful nutritional monitoring

Experts emphasize the importance of managing expectations and fostering healthy attitudes around food and body image.

Medication should be combined with lifestyle changes. Therapy may help avoid emotional complications.

More research is also needed to determine appropriate dosing and define which patients are most likely to benefit from Wegovy treatment. Ongoing assessment for both effectiveness and safety will be crucial.

Read More: Causes Of Restless Leg Syndrome: Are You Ignoring These Hidden Triggers?


More research is still needed to develop evidence-based recommendations on using Wegovy to treat pediatric obesity. The drug shows promise in helping adolescents achieve significant weight loss and improve obesity-related health complications.

However, there are numerous risks, such as unknown long-term safety, potential growth impairment, and psychological side effects that must be carefully weighed against any benefits.

While using Wegovy off-label to treat youth with obesity may be appropriate in some cases, it should be done cautiously and involve thorough medical monitoring and management of patient and family expectations. At this time, combining medication with lifestyle interventions appears to be the most prudent approach.

Additional data on the safety and efficacy of Wegovy specifically in pediatric populations will help guide responsible clinical use of this new obesity treatment in children and adolescents struggling with excess weight.

Frequently Asked Questions 

1. What age can you start Wegovy?

Wegovy is only FDA-approved for use in patients 18 years and older. Some doctors may prescribe it off-label for adolescents under 18, but more research is needed to establish safety and efficacy in pediatric populations.

2. What are the side effects of Wegovy in teens?

In a clinical trial of Wegovy in adolescents aged 12-17, the most common side effects were gastrointestinal issues like nausea, vomiting, diarrhea, and abdominal pain. Headache, fatigue, back pain, dizziness, and constipation also occurred.

3. Does Wegovy affect growth in children?

This is a potential concern but is currently unknown. One study found no negative impact on height after 56 weeks of treatment in adolescents. However long-term studies on the effects of Wegovy on growth and bone density in youth are needed.

4. How much weight can a child lose on Wegovy?

In the clinical trial, adolescents lost an average of 13 pounds over 56 weeks compared to a gain of 3 pounds for placebo. Individual results vary based on dosage, diet, exercise, and other factors.

5. Can Wegovy be used long-term in teens?

Long-term safety and efficacy have not been established in teens. In adults, Wegovy has only been studied for up to 68 weeks.

6. Is Wegovy approved for children under 12?

Long-term safety and efficacy have not been established in teens. In adults, Wegovy has only been studied for up to 68 weeks.

7. What should you monitor with pediatric Wegovy use?

Experts recommend monitoring height, weight, blood pressure, metabolic markers, thyroid levels, nutritional intake, psychology, and any side effects. Slowed growth is a potential risk.

8. Does insurance cover Wegovy for kids?

It depends on the plan. Since it is off-label for pediatric use, coverage may require a prior authorization process. Out-of-pocket costs may be high.

About the Author

Nicole Carter is a dedicated and passionate nutritionist, committed to helping individuals achieve their health and wellness goals through the power of proper nutrition. With a Bachelor's degree in Nutritional Science and years of practical experience.

Leave a Comment